The economics and efficiency of “doing more with less” are well understood across a broad array of scientific disciplines and technology platforms.  Fundamental to the core mission of  Protasis/MRM is the transfer of innovative application methodologies and component technologies from analytical techniques where miniaturization has been shown to provide clear advantage.  Capillary fluidic transport, tightly controlled fluidic pumps and valves, miniaturized detectors, and web-based automation and control software are all components and feature attributes borrowed from complementary techniques and applied to NMR to achieve similar advantage.  NMR has until this time remained historically rooted in tube-based samples and the need for milliliters and milligrams of material.  The ability to analyze microliters and micrograms means that you can focus your time on doing more NMR analysis without waiting for additional sample prep.  It means that you can more quickly analyze your synthesis product to make assessments earlier in the process.   It means that with less time for expression you can understand basic behavior attributes of your proteins so you can intelligently direct financial resources to the candidates that merit further analysis.  It means that you can time-track the biofluid data of one mouse rather than an ensemble average.  It means that you can accept microplate and microvial sample media formats compatible with other techniques so that NMR can added to the measurement chain without precondition for additional sample work-up.  It means that you might avoid the technician and quality control resources required to reconstitute to a previous format by simply not being required to “give back” the 5 mL you injected.  Simply put, it means that you can get information more quickly, information you need to make decisions to direct your resources more wisely.  It’s the economy of small size scale, and it’s a microflow CapNMR advantage.